

**BACKGROUND NOTE:** Each year WHO and UNICEF jointly review reports submitted by Member States regarding national immunization coverage, finalized survey reports as well as data from the published and grey literature. Based on these data, with due consideration to potential biases and the views of local experts, WHO and UNICEF attempt to distinguish between situations where the available empirical data accurately reflect immunization system performance and those where the data are likely to be compromised and present a misleading view of immunization coverage while jointly estimating the most likely coverage levels for each country.

WHO and UNICEF estimates are country-specific; that is to say, each country's data are reviewed individually, and data are not borrowed from other countries in the absence of data. Estimates are not based on ad hoc adjustments to reported data; in some instances empirical data are available from a single source, usually the nationally reported coverage data. In cases where no data are available for a given country/vaccine/year combination, data are considered from earlier and later years and interpolated to estimate coverage for the missing year(s). In cases where data sources are mixed and show large variation, an attempt is made to identify the most likely estimate with consideration of the possible biases in available data. For methods see:

\*Burton et al. 2009. WHO and UNICEF estimates of national infant immunization coverage: methods and processes.

\*Burton et al. 2012. A formal representation of the WHO and UNICEF estimates of national immunization coverage: a computational logic approach.

\*Brown et al. 2013. An introduction to the grade of confidence used to characterize uncertainty around the WHO and UNICEF estimates of national immunization coverage.

## DATA SOURCES.

**ADMINISTRATIVE coverage:** Reported by national authorities and based on aggregated administrative reports from health service providers on the number of vaccinations administered during a given period (numerator data) and reported target population data (denominator data). May be biased by inaccurate numerator and/or denominator data.

**OFFICIAL coverage:** Estimated coverage reported by national authorities that reflects their assessment of the most likely coverage based on any combination of administrative coverage, survey-based estimates or other data sources or adjustments. Approaches to determine OFFICIAL coverage may differ across countries.

**SURVEY coverage:** Based on estimated coverage from population-based household surveys among children aged 12-23 months or 24-35 months following a review of survey methods and results. Information is based on the combination of vaccination history from documented evidence or caregiver recall. Survey results are considered for the appropriate birth cohort based on the period of data collection.

## ABBREVIATIONS

**BCG:** percentage of births who received one dose of Bacillus Calmette Guerin vaccine.

**DTP1 / DTP3:** percentage of surviving infants who received the 1st / 3rd dose, respectively, of diphtheria and tetanus toxoid with pertussis containing vaccine.

**Pol3:** percentage of surviving infants who received the 3rd dose of polio containing vaccine. May be either oral or inactivated polio vaccine.

**IPV1:** percentage of surviving infants who received at least one dose of inactivated polio vaccine. In countries utilizing an immunization schedule recommending either (i) a primary series of three doses of oral polio vaccine (OPV) plus at least one dose of IPV where OPV is included in routine

immunization and/or campaign or (ii) a sequential schedule of IPV followed by OPV, WHO and UNICEF estimates for IPV1 reflect coverage with at least one routine dose of IPV among infants <1 year of age among countries. For countries utilizing IPV containing vaccine use only, i.e., no recommended dose of OPV, the WHO and UNICEF estimate for IPV1 corresponds to coverage for the 1st dose of IPV.

Production of IPV coverage estimates, which begins in 2015, results in no change of the estimated coverage levels for the 3rd dose of polio (Pol3). For countries recommending routine immunization with a primary series of three doses of IPV alone, WHO and UNICEF estimated Pol3 coverage is equivalent to estimated coverage with three doses of IPV. For countries with a sequential schedule, estimated Pol3 coverage is based on that for the 3rd dose of polio vaccine regardless of vaccine type.

**MCV1:** percentage of surviving infants who received the 1st dose of measles containing vaccine. In countries where the national schedule recommends the 1st dose of MCV at 12 months or later based on the epidemiology of disease in the country, coverage estimates reflect the percentage of children who received the 1st dose of MCV as recommended.

**MCV2:** percentage of children who received the 2nd dose of measles containing vaccine according to the nationally recommended schedule.

**RCV1:** percentage of surviving infants who received the 1st dose of rubella containing vaccine. Coverage estimates are based on WHO and UNICEF estimates of coverage for the dose of measles containing vaccine that corresponds to the first measles-rubella combination vaccine. Nationally reported coverage of RCV is not taken into consideration nor are the data represented in the accompanying graph and data table.

**HepBB:** percentage of births which received a dose of hepatitis B vaccine within 24 hours of delivery. Estimates of hepatitis B birth dose coverage are produced only for countries with a universal birth dose policy. Estimates are not produced for countries that recommend a birth dose to infants born to HepB virus-infected mothers only or where there is insufficient information to determine whether vaccination is within 24 hours of birth.

**HepB3:** percentage of surviving infants who received the 3rd dose of hepatitis B containing vaccine following the birth dose.

**Hib3:** percentage of surviving infants who received the 3rd dose of Haemophilus influenzae type b containing vaccine.


**RotaC:** percentage of surviving infants who received the final recommended dose of rotavirus vaccine, which can be either the 2nd or the 3rd dose depending on the vaccine.

**PcV3:** percentage of surviving infants who received the 3rd dose of pneumococcal conjugate vaccine. In countries where the national schedule recommends two doses during infancy and a booster dose at 12 months or later based on the epidemiology of disease in the country, coverage estimates may reflect the percentage of surviving infants who received two doses of PcV prior to the 1st birthday.

**YFV:** percentage of surviving infants who received one dose of yellow fever vaccine in countries where YFV is part of the national immunization schedule for children or is recommended in at risk areas; coverage estimates are annualized for the entire cohort of surviving infants.

Disclaimer: All reasonable precautions have been taken by the World Health Organization and United Nations Children's Fund to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization or United Nations Children's Fund be liable for damages arising from its use.

CIV - BCG



|                | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate       | 79   | 76   | 93   | 85   | 85   | 80   | 95   | 93   | 96   | 97   | 91   | 93   |
| Estimate GoC   | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    |
| Official       | 79   | 76   | 102  | 91   | 85   | 79   | 94   | 91   | 93   | 91   | 84   | 86   |
| Administrative | 79   | 76   | 102  | 91   | 85   | 79   | 94   | 91   | 93   | 91   | 84   | 86   |
| Survey         | NA   | 83   | 93   | *    | *    | NA   | NA   | 93   | NA   | NA   | 91   | NA   |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

## Description:

- 2021: Reported data calibrated to 2020 levels. Programme reports a two month vaccine stock-out. Estimate challenged by: D-R-
- 2020: Estimate of 91 percent assigned by working group. Estimate based on survey results. Estimate of 91 percent changed from previous revision value of 86 percent. Estimate challenged by: D-R-
- 2019: Reported data calibrated to 2017 and 2020 levels. Estimate of 97 percent changed from previous revision value of 93 percent. Estimate challenged by: D-R-
- 2018: Reported data calibrated to 2017 and 2020 levels. Estimate of 96 percent changed from previous revision value of 95 percent. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.
- 2017: Estimate of 93 percent assigned by working group. Estimate based on survey results. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.
- 2016: Reported data calibrated to 2014 and 2017 levels. Programme reports increasing vaccination sessions and other efforts to increase coverage levels and improve data quality. Increase may be the result of recovering from previous year BCG stock-out. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.
- 2015: Reported data calibrated to 2014 and 2017 levels. Programme reports three months stock-out at national level. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.
- 2014: Estimate based on coverage reported by national government supported by survey. Survey evidence of 83 percent based on 2 survey(s). Programme reports four month stock-out at national level. Estimate is based on reported data. Programme reports that the conduct of supplementary immunization activities for measles and meningitis A as well as enumeration activities during the second half of 2014 was a distraction for routine immunization service delivery. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.
- 2013: Estimate of 85 percent assigned by working group. Estimate based on survey result. Programme reports a two month stock-out at national level. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.
- 2012: Estimate of 93 percent assigned by working group. Estimate is based on survey results consistent with other antigens. Reported coverage might reflect recovery activities following the vaccine shortage in 2011. Estimate challenged by: R-
- 2011: Estimate based on coverage reported by national government supported by survey. Survey evidence of 83 percent based on 1 survey(s). Decline in coverage is attributable to vaccine shortages in 70 districts. Estimate challenged by: S-
- 2010: Estimate based on coverage reported by national government. Estimate challenged by: S-

# Côte d'Ivoire - DTP1

CIV - DTP1



|                | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate       | 87   | 74   | 93   | 83   | 92   | 96   | 98   | 93   | 95   | 92   | 84   | 85   |
| Estimate GoC   | ●●●  | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    |
| Official       | 87   | 74   | NA   | 103  | 92   | 97   | 99   | 95   | 100  | 100  | 95   | 96   |
| Administrative | 87   | 74   | NA   | 103  | 92   | 97   | 99   | 95   | 100  | 100  | 95   | 96   |
| Survey         | NA   | 78   | 93   | *    | *    | NA   | NA   | 93   | NA   | NA   | 84   | NA   |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

## Description:

- 2021: Reported data calibrated to 2020 levels. Programme reports a four month vaccine stock-out. Estimate challenged by: D-R-
- 2020: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 84 percent based on 1 survey(s). Estimate of 84 percent changed from previous revision value of 93 percent. Estimate challenged by: D-R-
- 2019: Reported data calibrated to 2017 and 2020 levels. Estimate of 92 percent changed from previous revision value of 98 percent. Estimate challenged by: D-R-
- 2018: Reported data calibrated to 2017 and 2020 levels. Estimate of 95 percent changed from previous revision value of 98 percent. Estimate challenged by: D-R-S-
- 2017: Estimate of 93 percent assigned by working group. Estimate based on survey results. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.
- 2016: Reported data calibrated to 2014 and 2017 levels. Programme reports increasing vaccination sessions and other efforts to increase coverage levels and improve data quality. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.
- 2015: Reported data calibrated to 2014 and 2017 levels. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.
- 2014: Estimate based on coverage reported by national government supported by survey. Survey evidence of 87 percent based on 2 survey(s). Programme reports seven month stock-out at national level. Survey results do not reflect a decline in coverage as might be expected. Programme reports that the conduct of supplementary immunization activities for measles and meningitis A as well as enumeration activities during the second half of 2014 was a distraction for routine immunization service delivery. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.
- 2013: Estimate of 83 percent assigned by working group. Estimate based on survey result. Reported data excluded because 103 percent greater than 100 percent. Estimate challenged by: D-R-
- 2012: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 93 percent based on 1 survey(s). Reported coverage might reflect recovery activities following the vaccine shortage in 2011. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.
- 2011: Estimate based on coverage reported by national government supported by survey. Survey evidence of 78 percent based on 1 survey(s). Decline in coverage is attributable to vaccine shortages in 70 districts. Estimate challenged by: S-
- 2010: Estimate based on coverage reported by national government. GoC=R+ S+ D+

# Côte d'Ivoire - DTP3

CIV - DTP3



|                | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate       | 78   | 61   | 82   | 75   | 73   | 79   | 87   | 83   | 84   | 81   | 75   | 76   |
| Estimate GoC   | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    |
| Official       | 78   | 61   | 94   | 100  | 85   | 91   | 97   | 93   | 96   | 94   | 90   | 91   |
| Administrative | 78   | 61   | 94   | 100  | 85   | 91   | 97   | 93   | 96   | 94   | 90   | 91   |
| Survey         | NA   | 64   | 82   | *    | *    | NA   | NA   | 83   | NA   | NA   | 75   | NA   |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.


## Description:

- 2021: Reported data calibrated to 2020 levels. Programme reports a four month vaccine stock-out. Estimate challenged by: D-R-
- 2020: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 75 percent based on 1 survey(s). Estimate of 75 percent changed from previous revision value of 80 percent. Estimate challenged by: D-R-
- 2019: Reported data calibrated to 2017 and 2020 levels. Estimate of 81 percent changed from previous revision value of 84 percent. Estimate challenged by: D-R-
- 2018: Reported data calibrated to 2017 and 2020 levels. Estimate of 84 percent changed from previous revision value of 86 percent. Estimate challenged by: D-R-
- 2017: Estimate of 83 percent assigned by working group. Estimate based on survey results. Estimate challenged by: D-R-
- 2016: Reported data calibrated to 2014 and 2017 levels. Programme reports increasing vaccination sessions and other efforts to increase coverage levels and improve data quality. Estimate challenged by: D-R-S-
- 2015: Reported data calibrated to 2014 and 2017 levels. Drop-out observed in the reported data is inconsistent with that observed in the most recent survey, particularly among those with HBRs where coverage levels would be expected to be highest. Estimate challenged by: D-R-
- 2014: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 73 percent based on 2 survey(s). Côte d'Ivoire Multiple Indicator Cluster Survey 2016 card or history results of 68 percent modified for recall bias to 69 percent based on 1st dose card or history coverage of 82 percent, 1st dose card only coverage of 74 percent and 3rd dose card only coverage of 62 percent. Programme reports seven month stock-out at national level. Survey results do not reflect a decline in coverage as might be expected. Government disagrees with WHO and UNICEF estimates. Programme reports that the conduct of supplementary immunization activities for measles and meningitis A as well as enumeration activities during the second half of 2014 was a distraction for routine immunization service delivery. Estimate challenged by: D-R-
- 2013: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 75 percent based on 2 survey(s). Final Report of Evaluation of a Vaccination Campaign against Measles, Cote d'Ivoire, 2014 card or history results of 82 percent modified for recall bias to 80 percent based on 1st dose card or history coverage of 89 percent, 1st dose card only coverage of 68 percent and 3rd dose card only coverage of 61 percent. Côte d'Ivoire Multiple Indicator Cluster Survey 2016 card or history results of 67 percent modified for recall bias to 69 percent based on 1st dose card or history coverage of 76 percent, 1st dose card only coverage of 63 percent and 3rd dose card only coverage of 57 percent. National programme reports vaccinating 100 percent of children. The programme highlights the conduct of seven weeks of intensification activities that allowed the programme to reach additional children during 2013 compared to previous years. Survey evidence for the 2013 birth cohort challenges the reported coverage level. Estimate challenged by: D-R-

- 2012: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 82 percent based on 1 survey(s). Reported coverage might reflect recovery activities following the vaccine shortage in 2011. Estimate challenged by: R-S-
- 2011: Estimate based on coverage reported by national government supported by survey. Survey evidence of 67 percent based on 1 survey(s). Côte d'Ivoire Demographic and Health and Multiple Indicator Cluster Survey 2011-2012 card or history results of 64 percent modified for recall bias to 67 percent based on 1st dose card or history coverage of 78 percent, 1st dose card only coverage of 65 percent and 3rd dose card only coverage of 56 percent. Decline in coverage is attributable to vaccine shortages in 70 districts. Estimate challenged by: S-
- 2010: Estimate based on coverage reported by national government. Estimate challenged by: S-

# Côte d'Ivoire - Pol3

CIV - Pol3



|                | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate       | 75   | 58   | 83   | 74   | 71   | 77   | 81   | 82   | 84   | 80   | 67   | 73   |
| Estimate GoC   | •••  | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    |
| Official       | 75   | 58   | 95   | 97   | 83   | 88   | 91   | 91   | 95   | 94   | 83   | 89   |
| Administrative | 75   | 58   | 95   | 97   | 83   | 88   | 91   | 91   | 95   | 94   | 83   | 89   |
| Survey         | NA   | 69   | 82   | *    | *    | NA   | NA   | 82   | NA   | NA   | 67   | NA   |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

## Description:

- 2021: Reported data calibrated to 2020 levels. Programme reports a four month OPV vaccine stock-out. Estimate challenged by: D-R-
- 2020: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 67 percent based on 1 survey(s). Programme reports a five month vaccine stock-out at national and subnational levels. Estimate of 67 percent changed from previous revision value of 74 percent. Estimate challenged by: D-R-
- 2019: Reported data calibrated to 2017 and 2020 levels. Estimate of 80 percent changed from previous revision value of 85 percent. Estimate challenged by: D-R-S-
- 2018: Reported data calibrated to 2017 and 2020 levels. Estimate of 84 percent changed from previous revision value of 86 percent. Estimate challenged by: D-R-S-
- 2017: Estimate of 82 percent assigned by working group. Estimate based on survey results. Estimate challenged by: D-R-
- 2016: Reported data calibrated to 2014 and 2017 levels. Programme reports increasing vaccination sessions and other efforts to increase coverage levels and improve data quality. Estimate challenged by: D-R-
- 2015: Reported data calibrated to 2014 and 2017 levels. Estimate challenged by: D-R-
- 2014: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 71 percent based on 2 survey(s). Côte d'Ivoire Multiple Indicator Cluster Survey 2016 card or history results of 63 percent modified for recall bias to 66 percent based on 1st dose card or history coverage of 79 percent, 1st dose card only coverage of 69 percent and 3rd dose card only coverage of 58 percent. Programme reports four month stock-out at national level. Government disagrees with WHO and UNICEF estimate. Estimate is based on trend in reported data. Programme reports that the conduct of supplementary immunization activities for measles and meningitis A as well as enumeration activities during the second half of 2014 was a distraction for routine immunization service delivery. Estimate challenged by: D-R-S-
- 2013: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 74 percent based on 2 survey(s). Final Report of Evaluation of a Vaccination Campaign against Measles, Cote d'Ivoire, 2014 card or history results of 78 percent modified for recall bias to 79 percent based on 1st dose card or history coverage of 83 percent, 1st dose card only coverage of 58 percent and 3rd dose card only coverage of 55 percent. Côte d'Ivoire Multiple Indicator Cluster Survey 2016 card or history results of 62 percent modified for recall bias to 69 percent based on 1st dose card or history coverage of 77 percent, 1st dose card only coverage of 60 percent and 3rd dose card only coverage of 54 percent. Programme reports two months stock-out at national level. Estimate challenged by: D-R-
- 2012: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 83 percent based on 1 survey(s). Vaccination Coverage Survey 2013 card or history results of 82 percent modified for recall bias to 83 percent based on 1st dose card or history coverage of 94 percent, 1st dose card only coverage of 88 percent and 3rd dose card only coverage of 78 percent. Reported coverage might reflect recovery activities


following the vaccine shortage in 2011. Estimate challenged by: R-S-

2011: Survey results likely contain doses administered during campaigns. Côte d'Ivoire Demographic and Health and Multiple Indicator Cluster Survey 2011-2012 card or history results of 69 percent modified for recall bias to 77 percent based on 1st dose card or history coverage of 91 percent, 1st dose card only coverage of 71 percent and 3rd dose card only coverage of 60 percent. Decline in coverage is attributable to vaccine shortages in 70 districts. Estimate challenged by: S-

2010: Estimate based on coverage reported by national government. GoC=R+ S+ D+

# Côte d'Ivoire - IPV1

CIV - IPV1



|                | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate       | NA   | NA   | NA   | NA   | NA   | 24   | 48   | 1    | 67   | 79   | 74   | 76   |
| Estimate GoC   | NA   | NA   | NA   | NA   | NA   | •    | •    | •    | •    | •    | •    | •    |
| Official       | NA   | NA   | NA   | NA   | NA   | 38   | 62   | 1    | 81   | 90   | 88   | 90   |
| Administrative | NA   | NA   | NA   | NA   | NA   | 38   | 62   | 1    | 81   | 90   | 88   | 90   |
| Survey         | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | 53   | NA   |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.


## Description:

Estimates for a dose of inactivated polio vaccine (IPV) begin in 2015 following the Global Polio Eradication Initiative's Polio Eradication and Endgame Strategic Plan: 2013-2018 which recommended at least one full dose or two fractional doses of IPV into routine immunization schedules as a strategy to mitigate the potential consequences should any re-emergence of type 2 poliovirus occur following the planned withdrawal of Sabin type 2 strains from oral polio vaccine (OPV).

- 2021: Reported data calibrated to 2018 levels. Programme reports a two month vaccine stock-out. Estimate challenged by: D-R-
- 2020: Reported data calibrated to 2018 levels. National vaccination coverage survey, Cote d'Ivoire (2021) results ignored by working group. Survey results inconsistent for IPV1 compared to other vaccine doses recommended at the same age. Estimate challenged by: D-R-
- 2019: Estimate is based on relative relationship between reported administrative and estimated DTP3 coverage applied to reported administrative coverage for IPV1. Estimate challenged by: D-R-
- 2018: Estimate of 67 percent assigned by working group. Estimate based on reported data adjusted for the difference between reported administrative and estimated DTP3 coverage. Programme reports five month vaccine stock-out at national level. . Estimate challenged by: D-R-
- 2017: . Programme reports 12 month vaccine stock-out. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.
- 2016: Reported data calibrated to 2018 levels. Programme reports increasing vaccination sessions and other efforts to increase coverage levels and improve data quality. Programme reports a 6 month IPV stock-out. Data reported exceptionally accepted due to year of introduction complicated by reported vaccine stock-outs. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.
- 2015: Reported data calibrated to 2018 levels. Inactivated polio vaccine introduced during 2015. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.

# Côte d'Ivoire - MCV1

CIV - MCV1



|                | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate       | 64   | 49   | 74   | 69   | 59   | 67   | 73   | 70   | 75   | 73   | 66   | 68   |
| Estimate GoC   | ●●●  | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    | ●    |
| Official       | 64   | 49   | 85   | 85   | 71   | 80   | 88   | 86   | 92   | 92   | 86   | 88   |
| Administrative | 64   | 49   | 85   | 85   | 71   | 80   | 88   | 86   | 92   | 92   | 86   | 88   |
| Survey         | NA   | 64   | 74   | *    | *    | NA   | NA   | 70   | NA   | NA   | 66   | NA   |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.


- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

## Description:

- 2021: Reported data calibrated to 2020 levels. Estimate challenged by: D-R-
- 2020: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 66 percent based on 1 survey(s). Estimate of 66 percent changed from previous revision value of 70 percent. Estimate challenged by: D-R-
- 2019: Reported data calibrated to 2017 and 2020 levels. Estimate of 73 percent changed from previous revision value of 76 percent. Estimate challenged by: D-R-
- 2018: Reported data calibrated to 2017 and 2020 levels. Estimate of 75 percent changed from previous revision value of 76 percent. Estimate challenged by: D-R-
- 2017: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 70 percent based on 1 survey(s). Estimate challenged by: D-R-
- 2016: Reported data calibrated to 2014 and 2017 levels. Programme reports increasing vaccination sessions and other efforts to increase coverage levels and improve data quality. Estimate challenged by: D-R-S-
- 2015: Reported data calibrated to 2014 and 2017 levels. Estimate challenged by: D-R-
- 2014: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 59 percent based on 2 survey(s). Programme reports five month stock-out at national level. Government disagrees with WHO and UNICEF estimate. Estimate is based on trend in reported data. Programme reports that the conduct of supplementary immunization activities for measles and meningitis A as well as enumeration activities during the second half of 2014 was a distraction for routine immunization service delivery. Estimate challenged by: D-R-S-
- 2013: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 69 percent based on 2 survey(s). Programme reports three month stock-out at national level. Estimate challenged by: D-R-
- 2012: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 74 percent based on 1 survey(s). Reported coverage might reflect recovery activities following the vaccine shortage in 2011. Estimate challenged by: R-S-
- 2011: Survey results likely contain doses administered during campaigns. Decline in coverage is attributable to vaccine shortages in 70 districts. Estimate challenged by: S-
- 2010: Estimate based on coverage reported by national government. GoC=R+ S+ D+

# Côte d'Ivoire - MCV2



## Description:

Coverage estimates for the second dose of measles containing vaccine are for children by the nationally recommended age.

2021: Estimate based on coverage reported by national government. Vaccine dose introduced in 2021. GoC=R+ D+

|                | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate       | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | 1    |
| Estimate GoC   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | ●●   |
| Official       | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | 1    |
| Administrative | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | 1    |
| Survey         | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   |


The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

# Côte d'Ivoire - RCV1

CIV - RCV1



## Description:

For this revision, coverage estimates for the first dose of rubella containing vaccine are based on WHO and UNICEF estimates of coverage of measles containing vaccine. Nationally reported coverage of rubella containing vaccine is not taken into consideration nor are they represented in the the accompanying graph and data table.

2021: Estimate based on estimated MCV1. Estimate challenged by: D-R-

2020: Estimate based on estimated MCV1. Estimate of 66 percent changed from previous revision value of 70 percent. Estimate challenged by: D-R-

2019: Estimate based on estimated MCV1. Estimate of 73 percent changed from previous revision value of 76 percent. Estimate challenged by: D-R-

2018: Estimate based on estimated MCV1. Rubella containing vaccine introduced in 2018. Estimate of 75 percent changed from previous revision value of 76 percent. Estimate challenged by: D-R-


|                | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate       | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | 75   | 73   | 66   | 68   |
| Estimate GoC   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | •    | •    | •    | •    |
| Official       | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   |
| Administrative | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   |
| Survey         | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | 66   | NA   |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

# Côte d'Ivoire - HepBB



## Description:

2021: Estimate based on coverage reported by national government. Estimate challenged by: D-  
 2020: Estimate based on coverage reported by national government. Estimate based on reported data following recent vaccine introduction. Programme reports a two month vaccine stock-out at national level. Estimate challenged by: D-  
 2019: Estimate based on coverage reported by national government. Hepatitis B birth dose introduced in 2019. GoC=Assigned by working group. Consistency with other antigens.


|                | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate       | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | 9    | 62   | 66   |
| Estimate GoC   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | ●    | ●    | ●    |
| Official       | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | 9    | 62   | 66   |
| Administrative | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | 9    | 62   | 66   |
| Survey         | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

CIV - HepB3



|                | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate       | 79   | 62   | 82   | 75   | 73   | 79   | 87   | 83   | 84   | 81   | 75   | 76   |
| Estimate GoC   | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    |
| Official       | 78   | 61   | 94   | 100  | 85   | 91   | 97   | 93   | 96   | 94   | 90   | 91   |
| Administrative | 78   | 61   | 94   | 100  | 85   | 91   | 97   | 93   | 96   | 94   | 90   | 91   |
| Survey         | NA   | NA   | 82   | *    | *    | NA   | NA   | 83   | NA   | NA   | 75   | NA   |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

## Description:

- 2021: Reported data calibrated to 2020 levels. Programme reports a four month vaccine stock-out. Estimate challenged by: D-R-
- 2020: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 75 percent based on 1 survey(s). Estimate of 75 percent changed from previous revision value of 80 percent. Estimate challenged by: D-R-
- 2019: Reported data calibrated to 2017 and 2020 levels. Estimate of 81 percent changed from previous revision value of 84 percent. Estimate challenged by: D-R-
- 2018: Reported data calibrated to 2017 and 2020 levels. Estimate of 84 percent changed from previous revision value of 86 percent. Estimate challenged by: D-R-
- 2017: Estimate of 83 percent assigned by working group. Estimate based on survey results. Estimate challenged by: D-R-
- 2016: Reported data calibrated to 2014 and 2017 levels. Programme reports increasing vaccination sessions and other efforts to increase coverage levels and improve data quality. Estimate challenged by: D-R-S-
- 2015: Reported data calibrated to 2014 and 2017 levels. Estimate challenged by: D-R-
- 2014: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 73 percent based on 2 survey(s). Côte d'Ivoire Multiple Indicator Cluster Survey 2016 card or history results of 68 percent modified for recall bias to 69 percent based on 1st dose card or history coverage of 82 percent, 1st dose card only coverage of 74 percent and 3rd dose card only coverage of 62 percent. Programme reports seven month stock-out at national level. Government disagrees with WHO and UNICEF estimates. Estimate is based on trend in reported data. Programme reports that the conduct of supplementary immunization activities for measles and meningitis A as well as enumeration activities during the second half of 2014 was a distraction for routine immunization service delivery. Estimate challenged by: D-R-
- 2013: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 75 percent based on 2 survey(s). Final Report of Evaluation of a Vaccination Campaign against Measles, Cote d'Ivoire, 2014 card or history results of 82 percent modified for recall bias to 80 percent based on 1st dose card or history coverage of 89 percent, 1st dose card only coverage of 68 percent and 3rd dose card only coverage of 61 percent. Côte d'Ivoire Multiple Indicator Cluster Survey 2016 card or history results of 67 percent modified for recall bias to 69 percent based on 1st dose card or history coverage of 76 percent, 1st dose card only coverage of 63 percent and 3rd dose card only coverage of 57 percent. National programme reports vaccinating 100 percent of children. The programme highlights the conduct of seven weeks of intensification activities that allowed the programme to reach additional children during 2013 compared to previous years. Survey evidence for the 2013 birth cohort challenges the reported coverage level. Estimate challenged by: D-R-
- 2012: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 82 percent based on 1 survey(s). Reported coverage might reflect recovery activities following the vaccine shortage in 2011. Estimate challenged by: R-

# Côte d'Ivoire - HepB3


---

2011: Estimate of 62 percent assigned by working group. Estimate based on DTP3 coverage level. Decline in coverage is attributable to vaccine shortages in 70 districts. Estimate challenged by: R-S-

2010: Reported data calibrated to 2009 and 2011 levels. Estimate challenged by: R-

# Côte d'Ivoire - Hib3

CIV - Hib3



|                | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate       | 79   | 62   | 82   | 75   | 73   | 79   | 87   | 83   | 84   | 81   | 75   | 76   |
| Estimate GoC   | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    |
| Official       | 78   | 61   | 94   | 100  | 85   | 91   | 97   | 93   | 96   | 94   | 90   | 91   |
| Administrative | 78   | 61   | 94   | 100  | 85   | 91   | 97   | 93   | 96   | 94   | 90   | 91   |
| Survey         | NA   | NA   | 82   | *    | *    | NA   | NA   | 83   | NA   | NA   | 75   | NA   |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

## Description:

- 2021: Reported data calibrated to 2020 levels. Programme reports a four month vaccine stock-out. Estimate challenged by: D-R-
- 2020: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 75 percent based on 1 survey(s). Estimate of 75 percent changed from previous revision value of 80 percent. Estimate challenged by: D-R-
- 2019: Reported data calibrated to 2017 and 2020 levels. Estimate of 81 percent changed from previous revision value of 84 percent. Estimate challenged by: D-R-
- 2018: Reported data calibrated to 2017 and 2020 levels. Estimate of 84 percent changed from previous revision value of 86 percent. Estimate challenged by: D-R-
- 2017: Estimate of 83 percent assigned by working group. Estimate based on survey results. Estimate challenged by: D-R-
- 2016: Reported data calibrated to 2014 and 2017 levels. Programme reports increasing vaccination sessions and other efforts to increase coverage levels and improve data quality. Estimate challenged by: D-R-S-
- 2015: Reported data calibrated to 2014 and 2017 levels. Estimate challenged by: D-R-
- 2014: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 73 percent based on 2 survey(s). Côte d'Ivoire Multiple Indicator Cluster Survey 2016 card or history results of 68 percent modified for recall bias to 69 percent based on 1st dose card or history coverage of 82 percent, 1st dose card only coverage of 74 percent and 3rd dose card only coverage of 62 percent. Programme reports seven month stock-out at national level. Government disagrees with WHO and UNICEF estimates. Estimate is based on trend in reported data. Programme reports that the conduct of supplementary immunization activities for measles and meningitis A as well as enumeration activities during the second half of 2014 was a distraction for routine immunization service delivery. Estimate challenged by: D-R-
- 2013: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 75 percent based on 2 survey(s). Final Report of Evaluation of a Vaccination Campaign against Measles, Cote d'Ivoire, 2014 card or history results of 82 percent modified for recall bias to 80 percent based on 1st dose card or history coverage of 89 percent, 1st dose card only coverage of 68 percent and 3rd dose card only coverage of 61 percent. Côte d'Ivoire Multiple Indicator Cluster Survey 2016 card or history results of 67 percent modified for recall bias to 69 percent based on 1st dose card or history coverage of 76 percent, 1st dose card only coverage of 63 percent and 3rd dose card only coverage of 57 percent. National programme reports vaccinating 100 percent of children. The programme highlights the conduct of seven weeks of intensification activities that allowed the programme to reach additional children during 2013 compared to previous years. Survey evidence for the 2013 birth cohort challenges the reported coverage level. Estimate challenged by: D-R-
- 2012: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 82 percent based on 1 survey(s). Reported coverage might reflect recovery activities following the vaccine shortage in 2011. Estimate challenged by: R-

# Côte d'Ivoire - Hib3


---

2011: Estimate of 62 percent assigned by working group. Estimate based on DTP3 coverage level. Decline in coverage is attributable to vaccine shortages in 70 districts. Estimate challenged by: R-S-

2010: Reported data calibrated to 2009 and 2011 levels. Estimate challenged by: R-

# Côte d'Ivoire - RotaC

CIV - RotaC



## Description:

- 2021: Reported data calibrated to 2020 levels. Programme reports a seven month vaccine stock-out. Estimate challenged by: D-R-
- 2020: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 65 percent based on 1 survey(s). Estimate of 65 percent changed from previous revision value of 77 percent. Estimate challenged by: D-R-
- 2019: Reported data calibrated to 2020 levels. Estimate of 60 percent changed from previous revision value of 70 percent. Estimate challenged by: D-R-
- 2018: Reported data calibrated to 2020 levels. Estimate of 51 percent changed from previous revision value of 59 percent. Estimate challenged by: D-R-S-
- 2017: Reported data calibrated to 2020 levels. Estimate of 30 percent changed from previous revision value of 40 percent. Estimate challenged by: D-R-


|                | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate       | NA   | NA   | NA   | NA   | NA   | NA   | NA   | 30   | 51   | 60   | 65   | 58   |
| Estimate GoC   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | •    | •    | •    | •    | •    |
| Official       | NA   | NA   | NA   | NA   | NA   | NA   | NA   | 52   | 73   | 82   | 87   | 80   |
| Administrative | NA   | NA   | NA   | NA   | NA   | NA   | NA   | 52   | 73   | 82   | 87   | 80   |
| Survey         | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | NA   | 65   | NA   |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

CIV - PcV3



|                | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate       | NA   | NA   | NA   | NA   | 2    | 70   | 80   | 81   | 80   | 74   | 64   | 57   |
| Estimate GoC   | NA   | NA   | NA   | NA   | •    | •    | •    | •    | •    | •    | •    | •    |
| Official       | NA   | NA   | NA   | NA   | 1    | 81   | 95   | 91   | 95   | 94   | 89   | 82   |
| Administrative | NA   | NA   | NA   | NA   | 1    | 81   | 95   | 91   | 95   | 94   | 89   | 82   |
| Survey         | NA   | NA   | NA   | NA   | 49   | NA   | NA   | 80   | NA   | NA   | 64   | NA   |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

## Description:

- 2021: Reported data calibrated to 2020 levels. Programme reports an eight month vaccine stock-out. Estimate challenged by: D-R-
- 2020: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 64 percent based on 1 survey(s). Estimate of 64 percent changed from previous revision value of 79 percent. Estimate challenged by: D-R-
- 2019: Reported data calibrated to 2017 and 2020 levels. Estimate of 74 percent changed from previous revision value of 84 percent. Estimate challenged by: D-R-
- 2018: Reported data calibrated to 2017 and 2020 levels. Estimate of 80 percent changed from previous revision value of 81 percent. Estimate challenged by: D-R-S-
- 2017: Estimate of 81 percent assigned by working group. Estimate based on survey results. Côte d'Ivoire Vaccination Coverage Survey 2018 card or history results of 80 percent modified for recall bias to 81 percent based on 1st dose card or history coverage of 92 percent, 1st dose card only coverage of 84 percent and 3rd dose card only coverage of 74 percent. Estimate of 81 percent changed from previous revision value of 82 percent. Estimate challenged by: D-R-
- 2016: Estimate based on reported coverage adjusted for the difference between reported administrative and estimated DTP3. Programme reports increasing vaccination sessions and other efforts to increase coverage levels and improve data quality. Estimate challenged by: D-R-S-
- 2015: Estimate is based on the reported PCV3 coverage adjusted for the difference between reported administrative and estimated coverage for DTP3. Estimate challenged by: D-R-S-
- 2014: Estimate of 2 percent assigned by working group. Pneumococcal conjugate vaccine introduced 30 September 2014. Estimate is based on reported data. Côte d'Ivoire Multiple Indicator Cluster Survey 2016 card or history results of 49 percent modified for recall bias to 50 percent based on 1st dose card or history coverage of 63 percent, 1st dose card only coverage of 58 percent and 3rd dose card only coverage of 46 percent. Programme reports that the conduct of supplementary immunization activities for measles and meningitis A as well as enumeration activities during the second half of 2014 was a distraction for routine immunization service delivery. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.

# Côte d'Ivoire - YFV

CIV - YFV



|                | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|----------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Estimate       | 64   | 49   | 73   | 61   | 52   | 54   | 62   | 68   | 73   | 70   | 64   | 65   |
| Estimate GoC   | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    | •    |
| Official       | 64   | 49   | 81   | 83   | 57   | 56   | 81   | 84   | 90   | 90   | 85   | 86   |
| Administrative | 64   | 49   | 81   | 83   | 57   | 56   | 81   | 84   | 90   | 90   | 85   | 86   |
| Survey         | NA   | 48   | 73   | *    | *    | NA   | NA   | 68   | NA   | NA   | 64   | NA   |

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

## Description:

- 2021: Reported data calibrated to 2020 levels. Estimate challenged by: D-R-
- 2020: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 64 percent based on 1 survey(s). Programme reports a three month vaccine stock-out at national and subnational levels. Estimate of 64 percent changed from previous revision value of 69 percent. Estimate challenged by: D-R-
- 2019: Reported data calibrated to 2017 and 2020 levels. Estimate of 70 percent changed from previous revision value of 74 percent. Estimate challenged by: D-R-
- 2018: Reported data calibrated to 2017 and 2020 levels. Estimate of 73 percent changed from previous revision value of 74 percent. Estimate challenged by: D-R-
- 2017: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 68 percent based on 1 survey(s). Estimate challenged by: D-R-
- 2016: Estimate is based on reported data adjusted for the difference between reported and estimated coverage for MCV1. Programme reports increasing vaccination sessions and other efforts to increase coverage levels and improve data quality. Estimate challenged by: D-R-
- 2015: Estimate of 54 percent assigned by working group. Estimate based on survey level. Programme reports three months stock-out at national level. Estimate challenged by: R-S-
- 2014: Estimate of 52 percent assigned by working group. Estimate based on survey level. Programme reports six month stock-out at national level. Estimate is based on trend in reported data. Programme reports that the conduct of supplementary immunization activities for measles and meningitis A as well as enumeration activities during the second half of 2014 was a distraction for routine immunization service delivery. Estimate challenged by: R-S-
- 2013: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 61 percent based on 2 survey(s). Programme reports four month stock-out at national level. Estimate challenged by: D-R-S-
- 2012: Estimate of 73 percent assigned by working group. Estimate is based on survey results consistent with other antigens. Reported coverage might reflect recovery activities following the vaccine shortage in 2011. Estimate challenged by: R-S-
- 2011: Estimate based on coverage reported by national government supported by survey. Survey evidence of 48 percent based on 1 survey(s). Decline in coverage is attributable to vaccine shortages in 70 districts. Estimate challenged by: S-
- 2010: Estimate based on coverage reported by national government. Increased coverage likely reflects catch-up activities following stock-out in the previous year. Estimate challenged by: S-

# Côte d'Ivoire - survey details

2020 Enquete nationale de couverture vaccinale systematique, Cote d'Ivoire  
2021

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | Card                | 80.2     | 12-23 m    | 1298   | 86         |
| BCG     | Card or History     | 90.7     | 12-23 m    | 1298   | 86         |
| BCG     | History             | 10.5     | 12-23 m    | 1298   | 86         |
| DTP1    | Card or History     | 84.3     | 12-23 m    | 1298   | 86         |
| DTP3    | Card                | 70.2     | 12-23 m    | 1298   | 86         |
| DTP3    | Card or History     | 75.4     | 12-23 m    | 1298   | 86         |
| DTP3    | History             | 5.2      | 12-23 m    | 1298   | 86         |
| HepB1   | Card or History     | 84.3     | 12-23 m    | 1298   | 86         |
| HepB3   | Card                | 70.2     | 12-23 m    | 1298   | 86         |
| HepB3   | Card or History     | 75.4     | 12-23 m    | 1298   | 86         |
| HepB3   | History             | 5.2      | 12-23 m    | 1298   | 86         |
| Hib1    | Card or History     | 84.3     | 12-23 m    | 1298   | 86         |
| Hib3    | Card                | 70.2     | 12-23 m    | 1298   | 86         |
| Hib3    | Card or History     | 75.4     | 12-23 m    | 1298   | 86         |
| Hib3    | History             | 5.2      | 12-23 m    | 1298   | 86         |
| IPV1    | Card                | 48       | 12-23 m    | 1298   | 86         |
| IPV1    | Card or History     | 52.8     | 12-23 m    | 1298   | 86         |
| IPV1    | History             | 4.8      | 12-23 m    | 1298   | 86         |
| MCV1    | Card                | 61.2     | 12-23 m    | 1298   | 86         |
| MCV1    | Card or History     | 65.8     | 12-23 m    | 1298   | 86         |
| MCV1    | History             | 4.6      | 12-23 m    | 1298   | 86         |
| PCV1    | Card or History     | 73.9     | 12-23 m    | 1298   | 86         |
| PCV3    | Card                | 58.9     | 12-23 m    | 1298   | 86         |
| PCV3    | Card or History     | 64.2     | 12-23 m    | 1298   | 86         |
| PCV3    | History             | 5.3      | 12-23 m    | 1298   | 86         |
| Pol1    | Card or History     | 78.2     | 12-23 m    | 1298   | 86         |
| Pol3    | Card                | 61.5     | 12-23 m    | 1298   | 86         |
| Pol3    | Card or History     | 66.7     | 12-23 m    | 1298   | 86         |
| Pol3    | History             | 5.2      | 12-23 m    | 1298   | 86         |
| RotaC   | Card                | 57.6     | 12-23 m    | 1298   | 86         |
| RotaC   | Card or History     | 64.9     | 12-23 m    | 1298   | 86         |
| RotaC   | History             | 7.3      | 12-23 m    | 1298   | 86         |
| YFV     | Card                | 59.9     | 12-23 m    | 1298   | 86         |
| YFV     | Card or History     | 64.5     | 12-23 m    | 1298   | 86         |
| YFV     | History             | 4.6      | 12-23 m    | 1298   | 86         |

2017 Enquete de Couverture Vaccinale Systématique 2018

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | Card                | 89.1     | 12-23 m    | 1312   | 90         |
| BCG     | Card or History     | 92.6     | 12-23 m    | 1312   | 90         |
| DTP1    | Card                | 84.8     | 12-23 m    | 1312   | 90         |
| DTP1    | Card or History     | 93.2     | 12-23 m    | 1312   | 90         |
| DTP3    | Card                | 75.8     | 12-23 m    | 1312   | 90         |
| DTP3    | Card or History     | 82.6     | 12-23 m    | 1312   | 90         |
| HepB1   | Card                | 84.8     | 12-23 m    | 1312   | 90         |
| HepB1   | Card or History     | 93.2     | 12-23 m    | 1312   | 90         |
| HepB3   | Card                | 75.8     | 12-23 m    | 1312   | 90         |
| HepB3   | Card or History     | 82.6     | 12-23 m    | 1312   | 90         |
| Hib1    | Card                | 84.8     | 12-23 m    | 1312   | 90         |
| Hib1    | Card or History     | 93.2     | 12-23 m    | 1312   | 90         |
| Hib3    | Card                | 75.8     | 12-23 m    | 1312   | 90         |
| Hib3    | Card or History     | 82.6     | 12-23 m    | 1312   | 90         |
| MCV1    | Card                | 64.9     | 12-23 m    | 1312   | 90         |
| MCV1    | Card or History     | 69.8     | 12-23 m    | 1312   | 90         |
| PcV1    | Card                | 84       | 12-23 m    | 1312   | 90         |
| PcV1    | Card or History     | 91.6     | 12-23 m    | 1312   | 90         |
| PCV3    | Card                | 73.5     | 12-23 m    | 1312   | 90         |
| PCV3    | Card or History     | 79.7     | 12-23 m    | 1312   | 90         |
| Pol1    | Card                | 84.1     | 12-23 m    | 1312   | 90         |
| Pol1    | Card or History     | 92.5     | 12-23 m    | 1312   | 90         |
| Pol3    | Card                | 74.9     | 12-23 m    | 1312   | 90         |
| Pol3    | Card or History     | 82.1     | 12-23 m    | 1312   | 90         |
| YFV     | Card                | 63.4     | 12-23 m    | 1312   | 90         |
| YFV     | Card or History     | 68.3     | 12-23 m    | 1312   | 90         |

2014 Côte d'Ivoire Multiple Indicator Cluster Survey 2016

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | C or H <12 months   | 78.3     | 12-23 m    | 1753   | 81         |
| BCG     | Card                | 67.9     | 12-23 m    | 1753   | 81         |
| BCG     | Card or History     | 78.3     | 12-23 m    | 1753   | 81         |

# Côte d'Ivoire - survey details

|       |                   |      |         |      |    |
|-------|-------------------|------|---------|------|----|
| BCG   | History           | 10.4 | 12-23 m | 1753 | 81 |
| DTP1  | C or H <12 months | 81.6 | 12-23 m | 1753 | 81 |
| DTP1  | Card              | 74.1 | 12-23 m | 1753 | 81 |
| DTP1  | Card or History   | 82.3 | 12-23 m | 1753 | 81 |
| DTP1  | History           | 8.2  | 12-23 m | 1753 | 81 |
| DTP3  | C or H <12 months | 65.9 | 12-23 m | 1753 | 81 |
| DTP3  | Card              | 62.5 | 12-23 m | 1753 | 81 |
| DTP3  | Card or History   | 67.9 | 12-23 m | 1753 | 81 |
| DTP3  | History           | 5.4  | 12-23 m | 1753 | 81 |
| HepB1 | C or H <12 months | 81.6 | 12-23 m | 1753 | 81 |
| HepB1 | Card              | 74.1 | 12-23 m | 1753 | 81 |
| HepB1 | Card or History   | 82.3 | 12-23 m | 1753 | 81 |
| HepB1 | History           | 8.2  | 12-23 m | 1753 | 81 |
| HepB3 | C or H <12 months | 65.9 | 12-23 m | 1753 | 81 |
| HepB3 | Card              | 62.5 | 12-23 m | 1753 | 81 |
| HepB3 | Card or History   | 67.9 | 12-23 m | 1753 | 81 |
| HepB3 | History           | 5.4  | 12-23 m | 1753 | 81 |
| Hib1  | C or H <12 months | 81.6 | 12-23 m | 1753 | 81 |
| Hib1  | Card              | 74.1 | 12-23 m | 1753 | 81 |
| Hib1  | Card or History   | 82.3 | 12-23 m | 1753 | 81 |
| Hib1  | History           | 8.2  | 12-23 m | 1753 | 81 |
| Hib3  | C or H <12 months | 65.9 | 12-23 m | 1753 | 81 |
| Hib3  | Card              | 62.5 | 12-23 m | 1753 | 81 |
| Hib3  | Card or History   | 67.9 | 12-23 m | 1753 | 81 |
| Hib3  | History           | 5.4  | 12-23 m | 1753 | 81 |
| MCV1  | C or H <12 months | 51.8 | 12-23 m | 1753 | 81 |
| MCV1  | Card              | 50.6 | 12-23 m | 1753 | 81 |
| MCV1  | Card or History   | 56.2 | 12-23 m | 1753 | 81 |
| MCV1  | History           | 5.6  | 12-23 m | 1753 | 81 |
| PCV1  | C or H <12 months | 61.6 | 12-23 m | 1753 | 81 |
| PCV1  | Card              | 58.4 | 12-23 m | 1753 | 81 |
| PCV1  | Card or History   | 63.1 | 12-23 m | 1753 | 81 |
| PCV1  | History           | 4.7  | 12-23 m | 1753 | 81 |
| PCV3  | C or H <12 months | 46.3 | 12-23 m | 1753 | 81 |
| PCV3  | Card              | 45.9 | 12-23 m | 1753 | 81 |
| PCV3  | Card or History   | 48.8 | 12-23 m | 1753 | 81 |
| PCV3  | History           | 2.9  | 12-23 m | 1753 | 81 |
| Pol1  | C or H <12 months | 78.9 | 12-23 m | 1753 | 81 |
| Pol1  | Card              | 68.8 | 12-23 m | 1753 | 81 |
| Pol1  | Card or History   | 79.2 | 12-23 m | 1753 | 81 |

|      |                   |      |         |      |    |
|------|-------------------|------|---------|------|----|
| Pol1 | History           | 10.3 | 12-23 m | 1753 | 81 |
| Pol3 | C or H <12 months | 61.1 | 12-23 m | 1753 | 81 |
| Pol3 | Card              | 58.3 | 12-23 m | 1753 | 81 |
| Pol3 | Card or History   | 62.6 | 12-23 m | 1753 | 81 |
| Pol3 | History           | 4.3  | 12-23 m | 1753 | 81 |
| YFV  | C or H <12 months | 47.9 | 12-23 m | 1753 | 81 |
| YFV  | Card              | 48.5 | 12-23 m | 1753 | 81 |
| YFV  | Card or History   | 53.9 | 12-23 m | 1753 | 81 |
| YFV  | History           | 5.4  | 12-23 m | 1753 | 81 |

## 2014 Revue Externe du Programme Elargi de Vaccination de Côte d'Ivoire 2015

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | Card                | 85       | 12-23 m    | 6416   | 91         |
| BCG     | Card or History     | 87       | 12-23 m    | 6416   | 91         |
| DTP1    | Card                | 84       | 12-23 m    | 6416   | 91         |
| DTP1    | Card or History     | 91       | 12-23 m    | 6416   | 91         |
| DTP3    | Card                | 70       | 12-23 m    | 6416   | 91         |
| DTP3    | Card or History     | 76       | 12-23 m    | 6416   | 91         |
| HepB1   | Card                | 84       | 12-23 m    | 6416   | 91         |
| HepB1   | Card or History     | 91       | 12-23 m    | 6416   | 91         |
| HepB3   | Card                | 70       | 12-23 m    | 6416   | 91         |
| HepB3   | Card or History     | 76       | 12-23 m    | 6416   | 91         |
| Hib1    | Card                | 84       | 12-23 m    | 6416   | 91         |
| Hib1    | Card or History     | 91       | 12-23 m    | 6416   | 91         |
| Hib3    | Card                | 70       | 12-23 m    | 6416   | 91         |
| Hib3    | Card or History     | 76       | 12-23 m    | 6416   | 91         |
| MCV1    | Card                | 57       | 12-23 m    | 6416   | 91         |
| MCV1    | Card or History     | 62       | 12-23 m    | 6416   | 91         |
| Pol3    | Card                | 70       | 12-23 m    | 6416   | 91         |
| Pol3    | Card or History     | 76       | 12-23 m    | 6416   | 91         |
| YFV     | Card                | 44       | 12-23 m    | 6416   | 91         |
| YFV     | Card or History     | 49       | 12-23 m    | 6416   | 91         |

## 2013 Côte d'Ivoire Multiple Indicator Cluster Survey 2016

# Côte d'Ivoire - survey details

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | C or H <12 months   | 78.5     | 24-35 m    | 1720   | 81         |
| BCG     | Card                | 61.7     | 24-35 m    | 1720   | 81         |
| BCG     | Card or History     | 79       | 24-35 m    | 1720   | 81         |
| BCG     | History             | 17.3     | 24-35 m    | 1720   | 81         |
| DTP1    | C or H <12 months   | 75.3     | 24-35 m    | 1720   | 81         |
| DTP1    | Card                | 62.8     | 24-35 m    | 1720   | 81         |
| DTP1    | Card or History     | 76.3     | 24-35 m    | 1720   | 81         |
| DTP1    | History             | 13.4     | 24-35 m    | 1720   | 81         |
| DTP3    | C or H <12 months   | 62.7     | 24-35 m    | 1720   | 81         |
| DTP3    | Card                | 57.2     | 24-35 m    | 1720   | 81         |
| DTP3    | Card or History     | 66.7     | 24-35 m    | 1720   | 81         |
| DTP3    | History             | 9.5      | 24-35 m    | 1720   | 81         |
| HepB1   | C or H <12 months   | 75.3     | 24-35 m    | 1720   | 81         |
| HepB1   | Card                | 62.8     | 24-35 m    | 1720   | 81         |
| HepB1   | Card or History     | 76.3     | 24-35 m    | 1720   | 81         |
| HepB1   | History             | 13.4     | 24-35 m    | 1720   | 81         |
| HepB3   | C or H <12 months   | 62.7     | 24-35 m    | 1720   | 81         |
| HepB3   | Card                | 57.2     | 24-35 m    | 1720   | 81         |
| HepB3   | Card or History     | 66.7     | 24-35 m    | 1720   | 81         |
| HepB3   | History             | 9.5      | 24-35 m    | 1720   | 81         |
| Hib1    | C or H <12 months   | 75.3     | 24-35 m    | 1720   | 81         |
| Hib1    | Card                | 62.8     | 24-35 m    | 1720   | 81         |
| Hib1    | Card or History     | 76.3     | 24-35 m    | 1720   | 81         |
| Hib1    | History             | 13.4     | 24-35 m    | 1720   | 81         |
| Hib3    | C or H <12 months   | 62.7     | 24-35 m    | 1720   | 81         |
| Hib3    | Card                | 57.2     | 24-35 m    | 1720   | 81         |
| Hib3    | Card or History     | 66.7     | 24-35 m    | 1720   | 81         |
| Hib3    | History             | 9.5      | 24-35 m    | 1720   | 81         |
| MCV1    | C or H <12 months   | 51.6     | 24-35 m    | 1720   | 81         |
| MCV1    | Card                | 51.1     | 24-35 m    | 1720   | 81         |
| MCV1    | Card or History     | 62.3     | 24-35 m    | 1720   | 81         |
| MCV1    | History             | 11.2     | 24-35 m    | 1720   | 81         |
| PCV1    | C or H <12 months   | 31.7     | 24-35 m    | 1720   | 81         |
| PCV1    | Card                | 28.5     | 24-35 m    | 1720   | 81         |
| PCV1    | Card or History     | 36.1     | 24-35 m    | 1720   | 81         |
| PCV1    | History             | 7.7      | 24-35 m    | 1720   | 81         |
| Pol1    | C or H <12 months   | 76.3     | 24-35 m    | 1720   | 81         |
| Pol1    | Card                | 60.5     | 24-35 m    | 1720   | 81         |
| Pol1    | Card or History     | 77.2     | 24-35 m    | 1720   | 81         |

|      |                   |      |         |      |    |
|------|-------------------|------|---------|------|----|
| Pol1 | History           | 16.7 | 24-35 m | 1720 | 81 |
| Pol3 | C or H <12 months | 58.2 | 24-35 m | 1720 | 81 |
| Pol3 | Card              | 54.5 | 24-35 m | 1720 | 81 |
| Pol3 | Card or History   | 62   | 24-35 m | 1720 | 81 |
| Pol3 | History           | 7.5  | 24-35 m | 1720 | 81 |
| YFV  | C or H <12 months | 37.6 | 24-35 m | 1720 | 81 |
| YFV  | Card              | 41.7 | 24-35 m | 1720 | 81 |
| YFV  | Card or History   | 52.5 | 24-35 m | 1720 | 81 |
| YFV  | History           | 10.8 | 24-35 m | 1720 | 81 |

## 2013 Republique de la Côte d'Ivoire Evaluation de la Campagne de Vaccination contre la Rougeole 2014 (Rapport Final)

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | Card                | 61.4     | 12-23 m    | -      | 75         |
| BCG     | Card or History     | 91.2     | 12-23 m    | 8787   | 75         |
| DTP1    | Card                | 67.5     | 12-23 m    | -      | 75         |
| DTP1    | Card or History     | 89.1     | 12-23 m    | 8787   | 75         |
| DTP3    | Card                | 61.1     | 12-23 m    | -      | 75         |
| DTP3    | Card or History     | 81.5     | 12-23 m    | 8787   | 75         |
| HepB1   | Card                | 67.5     | 12-23 m    | -      | 75         |
| HepB1   | Card or History     | 89.1     | 12-23 m    | 8787   | 75         |
| HepB3   | Card                | 61.1     | 12-23 m    | -      | 75         |
| HepB3   | Card or History     | 81.5     | 12-23 m    | 8787   | 75         |
| Hib1    | Card                | 67.5     | 12-23 m    | -      | 75         |
| Hib1    | Card or History     | 89.1     | 12-23 m    | 8787   | 75         |
| Hib3    | Card                | 61.1     | 12-23 m    | -      | 75         |
| Hib3    | Card or History     | 81.5     | 12-23 m    | 8787   | 75         |
| MCV1    | Card                | 54.6     | 12-23 m    | -      | 75         |
| MCV1    | Card or History     | 76.5     | 12-23 m    | 8787   | 75         |
| Pol1    | Card                | 57.6     | 12-23 m    | -      | 75         |
| Pol1    | Card or History     | 82.6     | 12-23 m    | 8787   | 75         |
| Pol3    | Card                | 54.8     | 12-23 m    | -      | 75         |
| Pol3    | Card or History     | 77.7     | 12-23 m    | 8787   | 75         |
| YFV     | Card                | 48.7     | 12-23 m    | -      | 75         |
| YFV     | Card or History     | 69.3     | 12-23 m    | 8787   | 75         |

## 2012 Enquête de Couverture Vaccinale 2013

# Côte d'Ivoire - survey details

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | Card                | 87       | 12-23 m    | -      | 88         |
| BCG     | Card or History     | 93       | 12-23 m    | 4751   | 88         |
| DTP1    | Card                | 88       | 12-23 m    | -      | 88         |
| DTP1    | Card or History     | 93       | 12-23 m    | 4751   | 88         |
| DTP3    | Card                | 78       | 12-23 m    | -      | 88         |
| DTP3    | Card or History     | 82       | 12-23 m    | 4751   | 88         |
| HepB1   | Card                | 88       | 12-23 m    | -      | 88         |
| HepB1   | Card or History     | 93       | 12-23 m    | 4751   | 88         |
| HepB3   | Card                | 78       | 12-23 m    | -      | 88         |
| HepB3   | Card or History     | 82       | 12-23 m    | 4751   | 88         |
| Hib1    | Card                | 88       | 12-23 m    | -      | 88         |
| Hib1    | Card or History     | 93       | 12-23 m    | 4751   | 88         |
| Hib3    | Card                | 78       | 12-23 m    | -      | 88         |
| Hib3    | Card or History     | 82       | 12-23 m    | 4751   | 88         |
| MCV1    | Card                | 71       | 12-23 m    | -      | 88         |
| MCV1    | Card or History     | 74       | 12-23 m    | 4751   | 88         |
| Pol1    | Card                | 88       | 12-23 m    | -      | 88         |
| Pol1    | Card or History     | 94       | 12-23 m    | 4751   | 88         |
| Pol3    | Card                | 78       | 12-23 m    | -      | 88         |
| Pol3    | Card or History     | 82       | 12-23 m    | 4751   | 88         |
| YFV     | Card                | 69       | 12-23 m    | -      | 88         |
| YFV     | Card or History     | 73       | 12-23 m    | 4751   | 88         |

## 2011 Enquête Démographique et de Santé et à Indicateurs Multiples EDSCI-III, Côte d'Ivoire, 2011-2012

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | C or H <12 months   | 82.9     | 12-23 m    | 1432   | 74         |
| BCG     | Card                | 68       | 12-23 m    | 1061   | 74         |
| BCG     | Card or History     | 83.4     | 12-23 m    | 1432   | 74         |
| BCG     | History             | 15.4     | 12-23 m    | 371    | 74         |
| DTP1    | C or H <12 months   | 76.8     | 12-23 m    | 1432   | 74         |
| DTP1    | Card                | 65.4     | 12-23 m    | 1061   | 74         |
| DTP1    | Card or History     | 77.5     | 12-23 m    | 1432   | 74         |
| DTP1    | History             | 12       | 12-23 m    | 371    | 74         |
| DTP3    | C or H <12 months   | 60       | 12-23 m    | 1432   | 74         |
| DTP3    | Card                | 56       | 12-23 m    | 1061   | 74         |

|      |                   |      |         |      |    |
|------|-------------------|------|---------|------|----|
| DTP3 | Card or History   | 63.8 | 12-23 m | 1432 | 74 |
| DTP3 | History           | 7.8  | 12-23 m | 371  | 74 |
| MCV1 | C or H <12 months | 49.2 | 12-23 m | 1432 | 74 |
| MCV1 | Card              | 52.6 | 12-23 m | 1061 | 74 |
| MCV1 | Card or History   | 64.5 | 12-23 m | 1432 | 74 |
| MCV1 | History           | 11.9 | 12-23 m | 371  | 74 |
| Pol1 | C or H <12 months | 90.7 | 12-23 m | 1432 | 74 |
| Pol1 | Card              | 71   | 12-23 m | 1061 | 74 |
| Pol1 | Card or History   | 91.4 | 12-23 m | 1432 | 74 |
| Pol1 | History           | 20.3 | 12-23 m | 371  | 74 |
| Pol3 | C or H <12 months | 64.8 | 12-23 m | 1432 | 74 |
| Pol3 | Card              | 60.4 | 12-23 m | 1061 | 74 |
| Pol3 | Card or History   | 69.2 | 12-23 m | 1432 | 74 |
| Pol3 | History           | 8.8  | 12-23 m | 371  | 74 |
| YFV  | C or H <12 months | 33.5 | 12-23 m | 1432 | 74 |
| YFV  | Card              | 47.7 | 12-23 m | 1061 | 74 |
| YFV  | Card or History   | 47.7 | 12-23 m | 1432 | 74 |
| YFV  | History           | 0    | 12-23 m | 371  | 74 |

## 2010 Enquête Démographique et de Santé et à Indicateurs Multiples EDSCI-III, Côte d'Ivoire, 2011-2012

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | C or H <12 months   | 84       | 24-35 m    | 1350   | 74         |
| DTP1    | C or H <12 months   | 79.4     | 24-35 m    | 1350   | 74         |
| DTP3    | C or H <12 months   | 61.5     | 24-35 m    | 1350   | 74         |
| MCV1    | C or H <12 months   | 52       | 24-35 m    | 1350   | 74         |
| Pol1    | C or H <12 months   | 89.6     | 24-35 m    | 1350   | 74         |
| Pol3    | C or H <12 months   | 63.8     | 24-35 m    | 1350   | 74         |

## 2009 Côte d'Ivoire Revue externe 2010 du Programme Elargi de Vaccination

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | Card                | 87       | 12-23 m    | -      | 91         |
| BCG     | Card <12 months     | 78       | 12-23 m    | -      | 91         |
| BCG     | Card or History     | 91       | 12-23 m    | 3455   | 91         |
| DTP1    | Card                | 78       | 12-23 m    | -      | 91         |
| DTP1    | Card <12 months     | 72       | 12-23 m    | -      | 91         |

# Côte d'Ivoire - survey details

|       |                 |    |         |      |    |
|-------|-----------------|----|---------|------|----|
| DTP1  | Card or History | 92 | 12-23 m | 3455 | 91 |
| DTP3  | Card            | 64 | 12-23 m | -    | 91 |
| DTP3  | Card <12 months | 53 | 12-23 m | -    | 91 |
| DTP3  | Card or History | 75 | 12-23 m | 3455 | 91 |
| HepB1 | Card            | 78 | 12-23 m | -    | 91 |
| HepB1 | Card <12 months | 72 | 12-23 m | -    | 91 |
| HepB1 | Card or History | 92 | 12-23 m | 3455 | 91 |
| HepB3 | Card            | 64 | 12-23 m | -    | 91 |
| HepB3 | Card <12 months | 53 | 12-23 m | -    | 91 |
| HepB3 | Card or History | 75 | 12-23 m | 3455 | 91 |
| MCV1  | Card            | 57 | 12-23 m | -    | 91 |
| MCV1  | Card <12 months | 40 | 12-23 m | -    | 91 |
| MCV1  | Card or History | 63 | 12-23 m | 3455 | 91 |
| Pol1  | Card            | 81 | 12-23 m | -    | 91 |
| Pol1  | Card <12 months | 74 | 12-23 m | -    | 91 |
| Pol1  | Card or History | 92 | 12-23 m | 3455 | 91 |
| Pol3  | Card            | 66 | 12-23 m | -    | 91 |
| Pol3  | Card <12 months | 55 | 12-23 m | -    | 91 |
| Pol3  | Card or History | 75 | 12-23 m | 3455 | 91 |
| YFV   | Card            | 36 | 12-23 m | -    | 91 |
| YFV   | Card <12 months | 24 | 12-23 m | -    | 91 |
| YFV   | Card or History | 41 | 12-23 m | 3455 | 91 |

## 2009 Enquête Démographique et de Santé et à Indicateurs Multiples EDSCI-III, Côte d'Ivoire, 2011-2012

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | C or H <12 months   | 79       | 36-47 m    | 1289   | 74         |
| DTP1    | C or H <12 months   | 71.8     | 36-47 m    | 1289   | 74         |
| DTP3    | C or H <12 months   | 54.2     | 36-47 m    | 1289   | 74         |
| MCV1    | C or H <12 months   | 47.8     | 36-47 m    | 1289   | 74         |
| Pol1    | C or H <12 months   | 83.7     | 36-47 m    | 1289   | 74         |
| Pol3    | C or H <12 months   | 56.6     | 36-47 m    | 1289   | 74         |

## 2008 Enquête Démographique et de Santé et à Indicateurs Multiples EDSCI-III, Côte d'Ivoire, 2011-2012

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | C or H <12 months   | 79.4     | 46-59 m    | 1250   | 74         |
| DTP1    | C or H <12 months   | 71.8     | 46-59 m    | 1250   | 74         |
| DTP3    | C or H <12 months   | 53.8     | 46-59 m    | 1250   | 74         |
| MCV1    | C or H <12 months   | 50.1     | 46-59 m    | 1250   | 74         |
| Pol1    | C or H <12 months   | 84.3     | 46-59 m    | 1250   | 74         |
| Pol3    | C or H <12 months   | 55       | 46-59 m    | 1250   | 74         |

## 2005 Enquête par grappes à indicateurs multiples, Côte d'Ivoire, 2006

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | C or H <12 months   | 85.1     | 12-23 m    | 1751   | 73         |
| BCG     | Card                | 72.2     | 12-23 m    | 1751   | 73         |
| BCG     | Card or History     | 85.4     | 12-23 m    | 1751   | 73         |
| BCG     | History             | 13.2     | 12-23 m    | 1751   | 73         |
| DTP1    | C or H <12 months   | 81       | 12-23 m    | 1751   | 73         |
| DTP1    | Card                | 71.6     | 12-23 m    | 1751   | 73         |
| DTP1    | Card or History     | 82.8     | 12-23 m    | 1751   | 73         |
| DTP1    | History             | 11.2     | 12-23 m    | 1751   | 73         |
| DTP3    | C or H <12 months   | 74.1     | 12-23 m    | 1751   | 73         |
| DTP3    | Card                | 66.5     | 12-23 m    | 1751   | 73         |
| DTP3    | Card or History     | 78.9     | 12-23 m    | 1751   | 73         |
| DTP3    | History             | 12.4     | 12-23 m    | 1751   | 73         |
| HepB1   | C or H <12 months   | 81       | 12-23 m    | 1751   | 73         |
| HepB1   | Card                | 71.6     | 12-23 m    | 1751   | 73         |
| HepB1   | Card or History     | 82.8     | 12-23 m    | 1751   | 73         |
| HepB1   | History             | 11.2     | 12-23 m    | 1751   | 73         |
| HepB3   | C or H <12 months   | 74.1     | 12-23 m    | 1751   | 73         |
| HepB3   | Card                | 66.5     | 12-23 m    | 1751   | 73         |
| HepB3   | Card or History     | 78.9     | 12-23 m    | 1751   | 73         |
| HepB3   | History             | 12.4     | 12-23 m    | 1751   | 73         |
| MCV1    | C or H <12 months   | 72.3     | 12-23 m    | 1751   | 73         |
| MCV1    | Card                | 67.7     | 12-23 m    | 1751   | 73         |
| MCV1    | Card or History     | 84.1     | 12-23 m    | 1751   | 73         |
| MCV1    | History             | 16.4     | 12-23 m    | 1751   | 73         |
| Pol1    | C or H <12 months   | 91.4     | 12-23 m    | 1751   | 73         |
| Pol1    | Card                | 70.8     | 12-23 m    | 1751   | 73         |
| Pol1    | Card or History     | 93.5     | 12-23 m    | 1751   | 73         |
| Pol1    | History             | 22.7     | 12-23 m    | 1751   | 73         |

# Côte d'Ivoire - survey details

|      |                   |      |         |      |    |
|------|-------------------|------|---------|------|----|
| Pol3 | C or H <12 months | 76.2 | 12-23 m | 1751 | 73 |
| Pol3 | Card              | 65.9 | 12-23 m | 1751 | 73 |
| Pol3 | Card or History   | 81.2 | 12-23 m | 1751 | 73 |
| Pol3 | History           | 15.2 | 12-23 m | 1751 | 73 |
| YFV  | C or H <12 months | 70.8 | 12-23 m | 1751 | 73 |
| YFV  | Card              | 73.5 | 12-23 m | 1751 | 73 |
| YFV  | Card or History   | 82.8 | 12-23 m | 1751 | 73 |
| YFV  | History           | 9.4  | 12-23 m | 1751 | 73 |

2000 Revue externe du PEV 2001

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | Card or History     | 87       | 12-23 m    | -      | 98         |
| DTP1    | Card or History     | 87       | 12-23 m    | -      | 98         |
| DTP3    | Card or History     | 70       | 12-23 m    | -      | 98         |
| MCV1    | Card or History     | 69       | 12-23 m    | -      | 98         |
| Pol3    | Card or History     | 70       | 12-23 m    | -      | 98         |

1999 Côte d'Ivoire, Enquête à Indicateurs Multiples MICS 2000

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | C or H <12 months   | 83       | 12-23 m    | 1588   | 77         |
| BCG     | Card                | 71.3     | 12-23 m    | 1588   | 77         |
| BCG     | Card or History     | 84.4     | 12-23 m    | 1588   | 77         |
| BCG     | History             | 13.1     | 12-23 m    | 1588   | 77         |
| DTP1    | C or H <12 months   | 74.8     | 12-23 m    | 1588   | 77         |
| DTP1    | Card                | 70.1     | 12-23 m    | 1588   | 77         |
| DTP1    | Card or History     | 78.7     | 12-23 m    | 1588   | 77         |
| DTP1    | History             | 8.6      | 12-23 m    | 1588   | 77         |
| DTP3    | C or H <12 months   | 56.5     | 12-23 m    | 1588   | 77         |
| DTP3    | Card                | 56       | 12-23 m    | 1588   | 77         |
| DTP3    | Card or History     | 61.9     | 12-23 m    | 1588   | 77         |
| DTP3    | History             | 5.9      | 12-23 m    | 1588   | 77         |
| MCV1    | C or H <12 months   | 53.2     | 12-23 m    | 1588   | 77         |
| MCV1    | Card                | 51.9     | 12-23 m    | 1588   | 77         |
| MCV1    | Card or History     | 61.5     | 12-23 m    | 1588   | 77         |
| MCV1    | History             | 9.6      | 12-23 m    | 1588   | 77         |
| Pol1    | C or H <12 months   | 82.5     | 12-23 m    | 1588   | 77         |

|      |                   |      |         |      |    |
|------|-------------------|------|---------|------|----|
| Pol1 | Card              | 71.4 | 12-23 m | 1588 | 77 |
| Pol1 | Card or History   | 85.7 | 12-23 m | 1588 | 77 |
| Pol1 | History           | 14.3 | 12-23 m | 1588 | 77 |
| Pol3 | C or H <12 months | 56.5 | 12-23 m | 1588 | 77 |
| Pol3 | Card              | 55   | 12-23 m | 1588 | 77 |
| Pol3 | Card or History   | 62   | 12-23 m | 1588 | 77 |
| Pol3 | History           | 7    | 12-23 m | 1588 | 77 |
| YFV  | Card              | 47.1 | 12-23 m | 1588 | 77 |
| YFV  | Card or History   | 48.5 | 12-23 m | 1588 | 77 |
| YFV  | History           | 1.4  | 12-23 m | 1588 | 77 |

1997 Enquête Démographique et de Santé, Côte d'Ivoire 1998-99, 2001

| Vaccine | Confirmation method | Coverage | Age cohort | Sample | Cards seen |
|---------|---------------------|----------|------------|--------|------------|
| BCG     | C or H <12 months   | 82       | 12-23 m    | 439    | 73         |
| BCG     | Card                | 69.9     | 12-23 m    | 439    | 73         |
| BCG     | Card or History     | 83.7     | 12-23 m    | 439    | 73         |
| BCG     | History             | 13.8     | 12-23 m    | 439    | 73         |
| DTP1    | C or H <12 months   | 79.7     | 12-23 m    | 439    | 73         |
| DTP1    | Card                | 68.6     | 12-23 m    | 439    | 73         |
| DTP1    | Card or History     | 82.9     | 12-23 m    | 439    | 73         |
| DTP1    | History             | 14.3     | 12-23 m    | 439    | 73         |
| DTP3    | C or H <12 months   | 54.9     | 12-23 m    | 439    | 73         |
| DTP3    | Card                | 53.7     | 12-23 m    | 439    | 73         |
| DTP3    | Card or History     | 60.9     | 12-23 m    | 439    | 73         |
| DTP3    | History             | 7.2      | 12-23 m    | 439    | 73         |
| MCV1    | C or H <12 months   | 51.3     | 12-23 m    | 439    | 73         |
| MCV1    | Card                | 57.2     | 12-23 m    | 439    | 73         |
| MCV1    | Card or History     | 66.2     | 12-23 m    | 439    | 73         |
| MCV1    | History             | 9        | 12-23 m    | 439    | 73         |
| Pol1    | C or H <12 months   | 82.5     | 12-23 m    | 439    | 73         |
| Pol1    | Card                | 69.8     | 12-23 m    | 439    | 73         |
| Pol1    | Card or History     | 86.3     | 12-23 m    | 439    | 73         |
| Pol1    | History             | 16.4     | 12-23 m    | 439    | 73         |
| Pol3    | C or H <12 months   | 54.6     | 12-23 m    | 439    | 73         |
| Pol3    | Card                | 53.5     | 12-23 m    | 439    | 73         |
| Pol3    | Card or History     | 60.6     | 12-23 m    | 439    | 73         |
| Pol3    | History             | 7.1      | 12-23 m    | 439    | 73         |

## Côte d'Ivoire - survey details

---

Further information and estimates for previous years are available at:

<https://data.unicef.org/topic/child-health/immunization/>

<https://immunizationdata.who.int/listing.html>